Press Releases

May 21, 2013
MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer

January 07, 2013
MacroGenics and Gilead Sciences Enter Strategic Alliance to Develop and Commercialize Four DART™ Products

September 20, 2012
MacroGenics and Servier Enter Broad Strategic Alliance to Develop and Commercialize Three Anti-Cancer DART™ Products

September 05, 2012
ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer Imaging partnership to focus on key immunology targets to diagnose multiple diseases

December 20, 2011
MacroGenics Receives Milestone Payment as Part of its Global DART Alliance with Boehringer Ingelheim

December 01, 2011
MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug

June 28, 2011
The Lancet Publishes Data from Protégé, MacroGenics’ Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients

June 23, 2011
MacroGenics Announces Presentation of Protégé Phase 3 Clinical Data at ADA in San Diego on June 28

April 28, 2011
Data Published in Blood Demonstrate Potent Activity of MacroGenics’ Proprietary DART™ Technology

January 06, 2011
MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients with HER2-Expressing Solid Tumors

Press Release Archive: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | View All